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Abstract The new derivatives of 3,4-pyridinedicarboxi-
mide were synthesised. Experimental measurements were
carried out using 1H NMR spectra, IR spectra, elemental
analyses and differential scanning calorimetry. The pur-
pose of this study was to study the thermal stability of these
four new compounds and to establish a solid-state poly-
morphism. Measurements were carried out for samples
obtained from ethanol and n-hexane and after a long-time
storage.
Keywords DSC  Polymorphism 
Pyridinedicarboximide  Thermal stability
Introduction
It was reported previously that the derivatives of 3,4-py-
ridinedicarboximide cause in animal tests significant
analgesic activity and do not display any noticeable toxic
effects (LD50 [ 2000 mg/kg) [1–3]. Over the last decade,
many similar compounds with structural modifications
have been synthesised. The relationship between structure
and pharmacological properties were investigated [4, 5]. In
the ‘writhing syndrome’ and ‘hot plate’ tests of those
compounds, they have exhibited potent analgesic activity,
which was superior to that of acetylsalicylic acid. What’s
more, the results of the ‘writhing syndrome’ test indicate
that the same compounds were more potent than morphine.
Furthermore, most of the investigated imides suppressed
significantly spontaneous locomotor activity in mice and
prolonged barbiturate sleep of these animals. The results of
the preliminary radioligand binding assay suggest that
these compounds display a weak affinity (in micromolar
concentration) to l-opioid receptors.
It would be of considerable importance to undertake
studies aiming at evaluation of the stability of that group of
compounds. A kinetic study of the degradation in aqueous
solution has shown that, either an acidic or basic medium,
at an increasing temperature, hydrolysis of the imide bonds
is observed [6–8]. However, solid form diversity of phar-
maceutical substances may influence the efficacy and
safety of drug products. Physical and chemical character-
ization of different solid phases that may occur during
crystallization and pharmaceutical formulation processes,
i.e. polymorphs, pseudo-polymorphism, solvates, desol-
vated solvates and amorphous materials is therefore
advisable for both drugs and excipients. It is very impor-
tant to control the crystal form of the drug during the
various stages of drug development, because any phase
changes and change in the degree of crystallinity can alter
the bioavailability of the drug. Thermal analysis is one of
the most frequently used instrumental techniques on
pharmaceutical researches to solve technological problems
[9–12]. The thermal analysis methods are widely used for
the study of the stability and decomposition of the sub-
stances used in medicine [13–25]. The evaluation of the
stability of a drug in solid form is realized especially by
analysing its decomposition in isothermal and non-iso-
thermal conditions.
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The four new derivatives of 3,4-pyridinedicarboximide were
synthesised (Fig. 1). A 0.5 g (0.002 mol) of 4-methoxy or
4-ethoxy-2,3-dihydro-6-methyl-1,3-dioxo-1H-pyrrolo[3,4-
c]pyridine was dissolved in 40 cm3 of tetrahydrofurane and
to this solution 1 cm3 of 33% formaline was added. The
mixture was refluxed for 0.5 h. After the time 0.0022 mol of
the suitable amine (4-benzylpiperazine or 4-(2-phenyl-
ethyl)piperazine) were added, again refluxed for 10 h. Then
the solvents were evaporated completely under reduced
pressure. The residue was purified by crystallization from the
solvent (ethanol and n-hexane).
1H NMR spectra were obtained on a 300 MHz Brucker
instrument. The samples were prepared by dissolving 5 mg
of each form in 600 ll of CDCl3. IR spectra (KBr cm
-1)
were recorded on a Specord M 80 (Carl Zeiss, Jena).
Elemental analyses were run on a Carlo Erba NA 1500
analyser and the results were within ±0.4% of the values
calculated for the corresponding formulas. The experi-
mental data are shown in Table 1.
Differential thermal analysis
The DSC traces were recorded on a Mettler Toledo DCS 25
measuring cell with TC15 TA Controller, calibrated with
indium to ensure the accuracy of the calorimetric scale.
Samples weighing 3–4 mg were characterized in sealed
40 lL aluminium pans with perforated lids and subjected
to thermal analysis under a flowing argon atmosphere
(30 cm3 min-1). Analysis was carried out from 303 K to
about 15 above melting temperature using heating rates of
5 and 10 K min-1 with an identical empty sample pan as
reference.
Results and discussion
In the IR spectra, all four compounds are clearly shown
characteristic peaks of imide’s carbonyl groups at 1715
(1720) and 1770 (1775) cm-1. We observe also benzene‘s
peaks at 695 (705) and 750 (755) cm-1. However, we do
not observe any peaks at 3050–3180 cm-1, where the peak
of imide’s N–H occurred, before condensation with suit-
able piperazine.
The NMR spectra all four compounds have characteristic
signals of piperazines, benzenes and other protons. In NMR
spectrum of compound 1, we can see multiple signal of
piperazine’s eight protons at 2.45–2.67 ppm, single signal
of three protons from CH3 (at 6) at 2.63 ppm, single signal
of two protons from CH2 (by benzene) at 3.48 ppm, single
signal of three protons from OCH3 at 4.13 ppm, single
signal of two protons from CH2 at 4.62 ppm and multiple
signal of benzene’s six protons at 7.18–7.26 ppm. In NMR
spectrum of compound 2, we can see triple signal of three
protons from OCH2CH3 at 1.42–1.47 ppm, multiple signal
of piperazine’s eight protons at 2.43–2.65 ppm, single sig-
nal of three protons from CH3 (at 6) at 2.59 ppm, single
signal of two protons from CH2 (by benzene) at 3.45 ppm,
multiple signal of four protons from OCH2CH3 and CH2 at
4.55–4.62 ppm and multiple signal of benzene’s six protons
at 7.13–7.25 ppm. In NMR spectrum of compound 3, we
can see multiple signal of fifteen protons from piperazine,
CH3 (at 6) and CH2CH2-benzene at 2.55–2.73 ppm, single
signal of three protons from OCH3 at 4.14 ppm, single
signal of two protons from CH2 at 4.64 ppm, and multiple
signal of benzene‘s six protons at 7.15–7.29 ppm. In NMR
spectrum of compound 4, we can see triple signal of three
protons of OCH2CH3 at 1.44–1.49 ppm, multiple signal of
fifteen protons of piperazine, CH3 (at 6) and CH2CH2-
benzene at 2.61–2.74 ppm, multiple signal of four protons
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signal of benzene’s six protons at 7.15–7.28 ppm. While we
cannot find signals at 7.74 and 10.47 ppm, where before
condensation with proper piperazine was presented proton
of imide nitrogen. So we can conclude, that synthesis those
four new compound is successfully ended.
Finally elemental analysis confirms these four struc-
tures: compound 1 Anal. Calcd for C21H24N4O3: C, 66.30;
H, 6.36; N, 14.73. Found: C, 66.39; H, 6.33; N, 14.37,
compound 2: Anal. Calcd for C22H26N4O3: C, 67.00; H,
6.64; N, 14.20. Found: C, 67.40; H, 6.73; N, 14.10, com-
pound 3: Anal. Calcd for C22H26N4O3: C, 67.00; H, 6.64;
N, 14.20. Found: C, 66.67; H, 6.47; N, 13.94., compound 4:
Anal. Calcd for C23H28N4O3: C, 67.62; H, 6.91; N, 13.72.
Found: C, 67.93; H, 7.05; N, 14.03.
Heat flow versus temperature has been measured for
four compounds in numerous experimental runs. In the first
step, samples were heated with 5 K min-1 rate, to com-
plete melting. Then heating was continued up to the
decomposition. The values of the melting point and purity
determined from these scans using the Purity option soft-
ware based on van’t Hoff equation (Table 2).
The temperature values of melting point are in a very
good agreement with the results obtained by elemental
analysis (Table 1). The DSC curves show only one endo-
thermic peak corresponding to the melting of pure com-
pounds. The differences in melting temperatures of
compounds obtained from different solvents are within the
limits of error, so it seems that solvent has no effect on the
crystallization of the compound. New samples of all sub-
stances sealed in ampoules and stored 1 year at room
temperature. After this time, they were measured by the
DSC method. The melting temperature and purity are
determined. For compounds 1, 2 and 4, temperature and
purity values are in a very good accordance with the data
obtained from the experiments carried out 1 year ago
(Table 2). Enthalpies of melting for compounds obtained
from different solvents and after 1 year of storage were
also determined. The values for each DSC scan are com-
parable: 82.3, 81.9 and 80.4 Jg-1 for compound 1 (ethanol,
n-hexane, 1 year, respectively); 96.7, 96.1 and 95.4 Jg-1
for compound 2; 61.0, 62.6 and 60.1 Jg-1 for compound 4.
The results indicated that those compounds are stable
















431–434 91 1715 705 2.45–2.67 (m-8H, H of piperazine); 2.63 (s-3H, CH3 at 6); 3.48 (s-2H,





429–432 85 1720 705 1.42–1.47 (t-3H, OCH2CH3); 2.43–2.65 (m-8H, H of piperazine); 2.59 (s-
3H, CH3 at 6); 3.45 (s-2H, CH2-benzene); 4.55–4.62 (m-4H, OCH2CH3




405–407 78 1715 695 2.55–2.73 (m-15H, H of piperazine, CH3 at 6 and CH2CH2-benzene); 4.14
(s-3H, OCH3); 4.64 (s-2H, CH2); 7.15–7.29 (m-6H, arom. H)1775 755
4 C23H28N4O3
(408.49)
370–373 66 1720 705 1.44–1.49 (t-3H, OCH2CH3); 2.61–2.74 (m-15H, H of piperazine, CH3 at 6
and CH2CH2-benzene); 4.57–4.64 (m-4H, OCH2CH3 and CH2);
7.15–7.28 (m-6H, arom. H)
1775 750
Table 2 DSC data for compound 1–4




1 431.1 (Ethanol) 99.2% 478.5 431.1 (Ethanol) 99.1%
431.0 (n-Hexane) 99.4% 431.0 (n-Hexane) 99.2%
2 429.9 (Ethanol) 99.1% 500.9 429.9 (Ethanol) 99.0%
430.0 (n-Hexane) 99.3% 430.1 (n-Hexane) 99.1%
3 402.6 (Ethanol) 99.3% 477.2 400.9, 415.1 (Ethanol) 99.0%
403.3 (n-Hexane) 99.2% 401.2, 414.4 (n-Hexane) 98.8%
4 369.4 (Ethanol) 99.4% 511.8 369.4 (Ethanol) 99.2%
369.3 (n-Hexane) 99.0% 369.2 (n-Hexane) 98.7%




















Fig. 2 DSC traces at
5 K min-1 for compound 2





















Fig. 3 DSC heating curves
5 K min-1 for compound 3
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Fig. 4 DSC heating curves
5 K min-1 for compound 3
(first heating and heating after
rapid cooling)
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during storage. The DSC scans illustrating these experi-
ments are shown on Fig. 2 (for compound 2).
The DSC curves measured for the compound 3 obtained
from ethanol, n-hexane and after 1 year storage are shown
on Fig. 3. The results for compound 3 are different than
that for compounds 1, 2 and 4. There is one exothermic
thermal effect on the DSC curve for the samples crystal-
lized from different solvents, at 402.6 K (ethanol) and
403.3 K (n-hexane). The enthalpies of melting are similar:
78.7 Jg-1 (ethanol) and 75.1 Jg-1 (n-hexane). The results
seem to indicate that the choice of solvent has no influence
on the crystallization of compound 3. The DSC measure-
ment of the sample stored about a year showed two exo-
thermic peaks at 400.9 and 415.1 K (ethanol). A lower
value is almost identical to the temperature obtained for the
samples crystallized from ethanol or n-hexane. For thermal
effect of this temperature, the value of enthalpy is equal to
46.1 Jg-1, it is about 60% lower than for the sample
measured a year ago. Two thermal effects on the DSC scan
can be due to partial decomposition of compound or phase
transition from the metastable form to the stable one during
the storage.
In accordance with Ostwald’s rule, the less stable
modifications are often formed first on the crystallizing
process from the melt. These rearrange then stepwise to the
stable form. Quite often, it is easier to obtain metastable
forms by slowly heating amorphous material (obtained by
shock cooling from the melt) above the glass transition
temperature [12, 26]. This procedure carried out for all
compounds.
The DSC scans for compound 3 are showed on Fig. 4. In
the first step, a sample is heated above melting temperature
with heating rate 5 K min-1 (dashed curve). One exo-
thermic thermal effect at temperature 400.9 K is observed.
After a shock cooling, the second measurement was carried
out. If the melting is rapid cooled quite often, instead of
crystals, glass is formed. On heating again at 5 K min-1 a
few thermal effects are observed. A single endothermic
peak has been detected at 365.1 K due to cold crystalli-
zation. On further heating the DSC trace shows two exo-
thermic peaks at 401.7 and 411.3 K corresponding to the
melting. It seems that this result is similar to that after
storage one (Fig. 3). This surprising result may suggest that
it is possible to say that the compound 3 has two crystal
forms: metastable modification and stable modification.
However, we were unable to obtain a sample containing
only stable form.
For compounds 1, 2 and 4 after heating and shock
cooling, the thermal effects are not detected on the DSC
curves. Those experiments were carried out immediately
after rapid cooling, after a week and after a month. In all
cases, no thermal effects were observed. The rapid cooling
of a liquid below its melting point may lead to an
amorphous state with structural characteristics of a liquid.
Since molecules in the amorphous state are thermody-
namically metastable relative to the crystalline state, the
potential for crystallization during handling and storage is
always present. However, the temperature at which optimal
nucleation and hence crystallization should occur will
depend on the degree below melting point and where the
temperature lies relative to glass transition temperature
[27–33]. At storage temperatures near to and above glass
transition, the rates of crystallization increased. On the
other hand, the temperature dependence of molecular
motions below the glass transition temperature is highly
dependent upon conditions under which the glass was
formed [27, 34–38]. Those molecular motions are conse-
quences of relaxation of a sample.
Conclusions
The derivatives of 3,4-pyridinedicarboximide are very
interesting materials due to their analgesic activity. In this
study, the DSC has been used to solid-state characterization
of four new compounds. The important aspects of our
investigation were stability and tendency or conditions for
crystallization in different crystalline forms (monotropic
polymorphism). The thermal analysis and calorimetric
methods offer great advantages for the study of polymor-
phism and pseudo-polymorphism. Only a few milligrams
of a sample per experiment are necessary. However, tran-
sitions of small energies or polymorphs are often not
detected. On the other hand, an amorphous solid with long
relaxation time is often obtained. In some cases, it may be
impossible to crystallize the material. From among the four
studied compounds, probably only the compound number 3
may occur different polymorphic form. DSC studies
showed significant differences during the rapid cooling
(crystallization). The rapid cooling did not cause re-crys-
tallization of compounds 1, 2 and 4. It should be noted,
however, that the crystallization of the amorphous form
depends on both barrier to crystallization and molecular
mobility [32]. On the other hand, only for the compound 3
measurements showed differences on the DSC curves after
a long-time storage (and only the compound 3 showed the
two exothermic effects on heating curves after rapid
cooling) probably due to two crystal forms: the metastable
modification and stable one. The stability of compounds 1,
2 and 4 after 1 year storage, to some extent indicates a lack
of the polymorphs forms.
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